Loading stock data…
$10.28-0.13 (-1.25%)
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases.
MoonLake Immunotherapeutics in the Healthcare sector is trading at $10.28 with a market capitalization of $1.1B. Wall Street consensus targets $28.54 (13 analysts), implying a +177.6% move over the next 12 months. The stock is currently near its 52-week low of $8.80, remaining 38.3% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 17 is oversold, raising the odds of a near-term bounce. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$61.66M↑ | -$70.02M↓ | -$65.22M↑ | -$71.43M↓ | -$60.70M |
| Net Income | -$61.80M↑ | -$69.71M↓ | -$62.43M↑ | -$69.73M↓ | -$55.22M |
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of in...